Paper Title
L.Acidophillus and Bifidobacterium SPP Contribute in The Treatment of Chronic Hepatitis C Patients

Abstract
Hepatitis C virus is a major leading cause of Liver pathogenesis. Probiotics showed a natural therapeutic activity against liver disorders. The antiviral and the antibacterial responses to L. acidophilus and Bifidobacteria spp in patients with chronic hepatitis C virus is a recommended study. Patients with chronic hepatitis C were treated with probiotics capsule that contains L. acidophilus and Bifidobacterium spp. They administered one capsule per day for a month before HCV treatment, blood and urine samples were collected before and after the given treatment and they were processed for a quantitative estimation of HCV by PCR, identification of bacteria by VITEK2 system and 16S r RNA gene sequencing assay, moreover, the estimation of antibacterial activity of probiotics, as well as counts of leukocytes, CD3+ T cells and CD56+ natural killer cells. Administration of Probiotics capsule enhanced the treatment response rate to HCV treatments as IFN-α and ribavirin by 25%. It had antibacterial activity against five species of the most common bacterial infections also It increased CD3+ cells counts and CD56+ natural killer cells in chronic HCV patients. Administration of probiotics as a capsule before HCV treatment can act as a supportive supplement with antiviral and antibacterial activities. Index Terms � CD3+; CD56+; Hepatitis C virus; Lactobacillus acidophilus; Bifidobacterium bifidum.